Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.7%

2 terminated out of 35 trials

Success Rate

88.2%

+1.7% vs benchmark

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

13%

2 of 15 completed with results

Key Signals

2 with results88% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (5)
P 2 (5)
P 3 (2)
P 4 (1)

Trial Status

Completed15
Unknown13
Recruiting3
Terminated2
Not Yet Recruiting1
Active Not Recruiting1

Trial Success Rate

88.2%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT07476885Not Yet RecruitingPrimary

A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases

NCT05144217Phase 2CompletedPrimary

Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo

NCT05517668Phase 2Terminated

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05060289RecruitingPrimary

A Prognostic Model for Drug-induced Liver Injury in China

NCT03100786Phase 3Completed

Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis

NCT02961413RecruitingPrimary

A Prospective Cohort Study on Drug-induced Liver Injury in China(DILI-P)

NCT06872372Not ApplicableActive Not Recruiting

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

NCT04964310Recruiting

Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study

NCT03211208CompletedPrimary

Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients

NCT03092817Phase 3Completed

Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)

NCT05465642UnknownPrimary

Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients

NCT06019936Phase 2UnknownPrimary

A Randomized,Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MT2004 Capsule in DILI Subjects

NCT05532345CompletedPrimary

Discrimination of DILI and AIH by Artificial Intelligence

NCT04553003Phase 4UnknownPrimary

Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial

NCT04625166Unknown

Combi-elastography Assessment of Chronic Liver Disease Multi-center Study

NCT03602703CompletedPrimary

Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs

NCT04302506UnknownPrimary

Correlative Cohort Study on the Clinical Features and Prognosis of Drug-induced Liver Injury

NCT03665402Not ApplicableCompleted

A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

NCT02182167Phase 2CompletedPrimary

A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis

NCT02299739CompletedPrimary

Liver Enzyme Abnormalities and Risk Factors in Taking Herbal Medicine

Scroll to load more

Research Network

Activity Timeline